POMALYST® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Safety profile of POMALYST + dex + elotuzumab vs POMALYST + dex alone.3

*For laboratory abnormalities, criteria must have been met for all grades or Grades 3/4.
†For adverse reactions, criteria were met for all grades.
- 43% of patients in the POMALYST + dex + elo arm experienced a heart rate of <60 bpm vs 22% of patients in the POMALYST + dex arm. 23% of patients in the POMALYST + dex + elo arm experienced a heart rate of ≥100 bpm vs 24% of patients in the POMALYST + dex arm
- The overall incidence of serious adverse reactions was 22% in patients treated with POMALYST + dex + elo and in 15% of patients treated with POMALYST + dex
- The most frequent serious adverse reactions were pneumonia (13% vs 11%) and respiratory tract infection (7% vs 3.6%); in the POMALYST + dex + elo vs POMALYST + dex arms, respectively
- 65% of patients treated in either arm experienced infections of any grade
- Grade 3/4 infections were reported in 13% of patients treated with POMALYST + dex + elo vs 22% of patients treated with POMALYST + dex
- Infusion reactions were reported in 3.3% of patients treated with POMALYST + dex + elo
- Median treatment duration was 9 cycles for POMALYST + dex + elo vs 5 cycles for POMALYST + dex, with a minimum follow-up of 9.1 months
5% of patients discontinued treatment due to adverse reactions with POMALYST + dex +
elotuzumab vs 1.8% with POMALYST + dex.
Information about POMALYST + dexamethasone + elotuzumab does not appear in the POMALYST Prescribing Information (PI). Please see the elotuzumab full PI for a discussion of Important Safety Information at www.empliciti.com.
Indication for POMALYST + dex + elo
POMALYST + dex + elo is indicated for the treatment of adult patients with MM who have received at least two prior therapies including lenalidomide and a PI.
Elotuzumab is associated with the following Warnings and Precautions: Infusion Reactions, Infections, Second Primary Malignancies (SPM), Hepatotoxicity, and Interference With Determination of Complete Response.
elo, elotuzumab; MM, multiple myeloma; PI, proteasome inhibitor.